Rodent models for ovarian cancer research
animal models; carcinoma cell-line; epithelial; gene-therapy; immunodeficient mice; luteinizing-hormone; lysophosphatidic acid; metastasis in-vivo; mouse models; neoplasms; nude-mice; Obstetrics & Gynecology; Oncology; ovarian-cancer; p53; review; tumor-associated antigens
Animal models that are biologically and clinically relevant are essential for conducting research to investigate the pathophysiologic progression of disease and to develop diagnostic or therapeutic strategies. Several rodent models that vary in methods of induction allow appropriate in vivo evaluation for ovarian cancer. The types of rodent models discussed include chemically (nonhormonal and hormonal) induced, genetic (knockout and transgenic), xenograft, and syngeneic. A summary of the available rodent models is provided with a discussion of the advantages and disadvantages of each. Optimization and application of these rodent models to future research may benefit the detection and treatment of ovarian cancer.
Stakleff K D S; Von Gruenigen V E
International Journal of Gynecological Cancer
2003
2003-07
Journal Article
<a href="http://doi.org/10.1046/j.1525-1438.2003.13317.x" target="_blank" rel="noreferrer noopener">10.1046/j.1525-1438.2003.13317.x</a>
Cysteinyl leukotriene 2 receptor promotes endothelial permeability, tumor angiogenesis, and metastasis.
*angiogenesis; *cysteinyl leukotriene receptors; *endothelial cells; *metastasis; *tumor growth; Male; Animals; Mice; Gene Knockout Techniques; Lung Neoplasms/drug therapy; Neoplasm Transplantation; Neoplasms; Receptors; Inbred C57BL; Neovascularization; Experimental; Capillary Permeability/drug effects; Cyclohexanecarboxylic Acids/pharmacology; Endothelial Cells/*drug effects; Leukotriene Antagonists/pharmacology; Neoplasm Metastasis/drug therapy; Phthalic Acids/pharmacology; Leukotriene/drug effects/*metabolism; Pathologic/*chemically induced/drug therapy
Cysteinyl leukotrienes (cys-LTs) are proinflammatory mediators that enhance vascular permeability through distinct receptors (CysLTRs). We found that CysLT2R regulates angiogenesis in isolated mouse endothelial cells (ECs) and in Matrigel implants in WT mice and enhances EC contraction and permeability via the Rho-dependent myosin light chain 2 and vascular endothelial (VE)-cadherin axis. Since solid tumors utilize aberrant angiogenesis for their growth and metastasis and their vessels exhibit vascular hyperpermeability, we hypothesized that CysLT2R, via its actions on the endothelium, might regulate tumor growth. Both tumor growth and metastases of adoptively transferred syngeneic Lewis lung carcinoma (LLC) cells are significantly reduced in CysLT2R-null mice (Cysltr2 (-/-)) compared with WT and CysLT1R-null mice (Cysltr1 (-/-)). In WT recipients of LLC cells, CysLT2R expression is significantly increased in the tumor vasculature, compared with CysLT1R. Further, the tumor vasculature in Cysltr2 (-/-) recipients exhibited significantly improved integrity, as revealed by increased pericyte coverage and decreased leakage of i.v.-administered Texas Red-conjugated dextran. Administration of a selective CysLT2R antagonist significantly reduced LLC tumor volume, vessel density, dextran leakage, and metastases in WT mice, highlighting CysLT2R as a VEGF-independent regulator of the vasculature promoting risk of metastasis. Thus, both genetic and pharmacological findings establish CysLT2R as a gateway for angiogenesis and EC dysregulation in vitro and ex vivo and in an in vivo model with a mouse tumor. Our data suggest CysLT2R as a possible target for intervention.
Duah Ernest; Teegala Lakshminarayan Reddy; Kondeti Vinay; Adapala Ravi K; Keshamouni Venkateshwar G; Kanaoka Yoshihide; Austen K Frank; Thodeti Charles K; Paruchuri Sailaja
Proceedings of the National Academy of Sciences of the United States of America
2019
2019-01
<a href="http://doi.org/10.1073/pnas.1817325115" target="_blank" rel="noreferrer noopener">10.1073/pnas.1817325115</a>
Diagnosis at a glance.
Male; Aged; Infant; Neoplasms; Ear – Abnormalities; Fibrous Tissue – Diagnosis; Hearing Disorders – Diagnosis – In Infancy and Childhood
Park Y W; Park KK; Cordova R; Schleicher S
Emergency Medicine (00136654)
2009
2009-03
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Relationship between breast cancer and meningioma.
Aged; Breast Neoplasms/*diagnosis; Carcinoma; Female; Humans; Intraductal; Meningeal Neoplasms/*diagnosis; Meningioma/*diagnosis; Middle Aged; Neoplasms; Noninfiltrating/*diagnosis; Ovarian Neoplasms/diagnosis; Second Primary/*diagnosis; Time Factors
Several authors have suggested the existence of a relationship between breast cancer and meningioma occurring in the same patient. I describe four patients who had both of these neoplasms and present findings that dispute the implied relationship between the two.
Smith-Behn J
Southern medical journal
1992
1992-02
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1097/00007611-199202000-00007" target="_blank" rel="noreferrer noopener">10.1097/00007611-199202000-00007</a>
Functioning liver metastases on an I-131 whole-body scan: a case of malignant struma ovarii.
*Iodine Radioisotopes; *Radiopharmaceuticals; *Whole-Body Irradiation; Adenoma/diagnosis; Female; Humans; Liver Neoplasms/diagnostic imaging/*secondary; Middle Aged; Multiple Primary/diagnosis; Neoplasms; Ovarian Neoplasms/*diagnostic imaging; Radionuclide Imaging; Struma Ovarii/diagnostic imaging/*secondary; Thyroid Neoplasms/diagnosis
A 46-year-old women was examined for severe constipation. Pelvic examination revealed a large pelvic mass extending to the level of the umbilicus. Computed tomography showed a large multicystic, septated mass in the pelvis and a small amount of fluid in the cul de sac. In addition, multiple ill-defined, mixed-attenuation hepatic lesions were identified. A malignant ovarian neoplasm with liver metastases was considered, so the pelvic mass was resected. Interestingly, histopathologic analysis revealed malignant struma ovarii of the follicular type. Biopsy of the liver lesions confirmed metastatic disease with similar histopathologic findings. All thyroid laboratory values were in the normal range. The patient then had a total thyroidectomy to optimize thyroid ablation therapy with I-131. This revealed a small follicular adenoma but no evidence of cancer. An I-131 whole-body scan was performed and showed uptake in multiple functioning liver metastases.
Konez O; Hanelin L G; Jenison E L; Goyal M; Randolph W
Clinical nuclear medicine
2000
2000-06
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1097/00003072-200006000-00014" target="_blank" rel="noreferrer noopener">10.1097/00003072-200006000-00014</a>
Vanadium in the detection, prevention and treatment of cancer: the in vivo evidence.
10-Dimethyl-1; 2-benzanthracene; 9; Animal; Animals; Biological; Breast Neoplasms – Chemically Induced; Breast Neoplasms – Diagnosis; Breast Neoplasms – Drug Therapy; Cell Division – Drug Effects; Cell Division/drug effects; Disease Models; Experimental/chemically induced/diagnosis/drug therapy; Experimental/drug therapy/pathology; Female; Glioblastoma/drug therapy; Glioma – Drug Therapy; Heterologous; Humans; Hydrocarbons; Male; Mammary Neoplasms; Metals; Metals – Diagnostic Use; Metals – Therapeutic Use; Models; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplasms – Diagnosis; Neoplasms – Drug Therapy; Neoplasms – Pathology; Neoplasms – Prevention and Control; Neoplasms/*diagnosis/drug therapy/prevention & control; Organometallic Compounds – Therapeutic Use; Organometallic Compounds/therapeutic use; Rats; Trace Elements – Diagnostic Use; Trace Elements – Therapeutic Use; Trace Elements/therapeutic use; Transplantation; Vanadium Compounds; Vanadium Compounds – Therapeutic Use; Vanadium Compounds/therapeutic use/toxicity; Vanadium/*therapeutic use/toxicity; Xenografts
Vanadium, a dietary micronutrient, is yet to be established as an essential part of the human diet. Over the past century, several biological effects of vanadium, such as insulin-mimetic action as well as amelioration of hyperlipidemia and hypertension, have been discovered. This transition element is known to influence a battery of enzymatic systems, namely phosphatases, ATPases, peroxidases, ribonucleases, protein kinases and oxidoreductases. Multiple biochemical and molecular actions of vanadium have been implicated in its inhibitory effects on various tumor cells of human origin. Successful in vitro studies over the past few decades have advanced the anticancer research on vanadium into the preclinical stage. Vanadium in several animal cancer models provides protection against all stages of carcinogenesis–initiation, promotion, and progression. This review focuses on the current advances in cancer prevention and treatment as well as early detection by vanadium compounds in preclinical animal models while pointing to possible mechanisms of such diverse beneficial effects. Clinical pharmacokinetic and potential toxicity studies on vanadium are also highlighted in this review. Supporting and challenging evidence as well as future directions of vanadium research exploring the possibility of using this dietary agent for detection, prevention and treatment of human cancers are critically discussed.
Bishayee Anupam; Waghray Abhijeet; Patel Mehool A; Chatterjee Malay
Cancer letters
2010
2010-08
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1016/j.canlet.2010.01.030" target="_blank" rel="noreferrer noopener">10.1016/j.canlet.2010.01.030</a>
Counseling patients about sun protection related to an active outdoor life: comment on "environmental cues to ultraviolet radiation and personal sun protection in outdoor winter recreation".
*Radiation Dosage; *Skiing; Altitude; Counseling; Humans; Neoplasms; Radiation-Induced/prevention & control; Skin Neoplasms/prevention & control; Sunscreening Agents/*administration & dosage; Ultraviolet Rays/adverse effects
Mostow Eliot N
Archives of dermatology
2010
2010-11
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1001/archdermatol.2010.305" target="_blank" rel="noreferrer noopener">10.1001/archdermatol.2010.305</a>